NYSE · IQV
IQVIA Holdings Inc.
Healthcare · Medical - Diagnostics & Research
$258.44▼ 3.33% ($8.89)at close
Pre-market$259.70▲ 0.49%4:57 AM ET
Valuation
Cash-flow DCF
Verdict: fairly priced. Price between Bear and Base.
The price needs 0.1% free cash flow growth a year for 5 years. Our scenarios assume 4.0–25.0%.
That's below its past 10-year pace of 19.0%.
Value per share
Base case
$686.81
Price used $258.44 is 62% below this
USD · TTM ending Sep 30, 2026 · Price Nov 2, 9:00 PM UTC
Reported total debt includes capitalised leases (~2% of the total). They are excluded from net debt and from the WACC weights because rent is already charged inside operating income. The Net Debt shown here is therefore lower than the balance-sheet figure elsewhere on this page.
Free cash flow each value needs
Free cash flow today $2.6B. The price needs $4.3B by 2036. Base case: $10.1B. At its recent pace: $14.7B. Bear to Bull: $3.7B to $15B.
Free cash flow today $2.6B. The price needs $4.3B by 2036. Base case: $10.1B. At its recent pace: $14.7B. Bear to Bull: $3.7B to $15B.
Free cash flow in 2036
today $2.6B
−$5.9Bless than the Base case
Value per share · Base case
$686.81
Price $258.44
62% below this
- Stage 1 growth, yrs 1–5
- 19.0%
- Stage 2 growth, yrs 6–10
- 10.5%
- Discount rate
- 8.3%
Reported total debt includes capitalised leases (~2% of the total). They are excluded from net debt and from the WACC weights because rent is already charged inside operating income. The Net Debt shown here is therefore lower than the balance-sheet figure elsewhere on this page.
USD · TTM ending Sep 30, 2026 · Price Nov 2, 9:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 20.83% over the last year. Revenue grew 8.85% over the trailing twelve months. Operating margin moved from 13.71% to 13.42%. Free cash flow declined 21.25% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 13.42%. A decisive move in revenue — currently up 8.85% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
37
Buy
7
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Feb 4, 2027
Q4 FY26 · EPS est $3.60 · Revenue est $4.5B
Same quarter, year over year
FY26 YTD +10.3%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q3 combined $9.39 vs $8.51 · all 3 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
FY25
FY24
FY23
—
—
—
—
Fiscal year totals
- FY25
- $11.93
- +7.1%
- FY24
- $11.14
- —
Q3 FY26
Reported Oct 27, 2026 · Latest
HoverTap a cell to inspect
Actual
$3.34
Estimate
$3.26
Year over year
+11.3%
Vs prior quarter
+6.0%
Institutional Sentiment
IQVIA Holdings Inc. · IQV
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.